Arrowhead Pharmaceuticals (ARWR) Metrics: History & Chart

Arrowhead Pharmaceuticals, Inc.(ARWR)

Biotechnology · Pasadena, CA

$62.76+0.41 (+0.66%)

Delayed quote: Oct 6, 2026, 9:30 AM EDT

About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.

Pasadena, CA

711 employees

arrowheadpharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Christopher R. Anzalone

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-4.75%
30D Total Return	-27.79%
YTD Total Return	-6.09%
1Y Total Return	+72.62%
3Y Total Return	+144.02%
5Y Total Return	+3.81%
10Y Total Return	+729.18%
15Y Total Return	+1499.71%
20Y Total Return	+31.54%

2026	-6.09%
2025	+253.14%
2024	-38.56%
2023	-24.56%
2022	-38.82%
2021	-13.59%
2020

CAGR TTM	+72.17%
CAGR 3Y	+34.62%
CAGR 5Y	+0.75%
CAGR 10Y	+23.56%
CAGR 15Y	+20.30%
CAGR 20Y	+1.38%

PE Ratio	50.62
PE Ratio Avg TTM	41.90
PE Ratio Avg 3Y	41.90
Current VS TTM Avg	+20.80%
Current VS 3Y Avg	+20.80%
Current VS 5Y Avg	+20.80%

All Metrics

ARWR Valuation Metrics

ARWR Stock Price Metrics

ARWR Dividend Metrics

ARWR Growth Rate Metrics

ARWR Discounted Cash Flow Metrics

ARWR Returns By Period

ARWR Yearly Returns

ARWR Average Annual Returns By Period (CAGR)

ARWR Revenue Metrics

ARWR PE Ratio Metrics

ARWR PS Ratio Metrics

ARWR PB Ratio Metrics

ARWR Price to Free Cash Flow Ratio Metrics

ARWR Debt to Equity Ratio Metrics

ARWR PEG Ratio Metrics

ARWR FCF Yield

ARWR Earnings Yield

ARWR EBITDA Yield

ARWR OCF Yield

ARWR EV/EBIT Ratio Metrics

ARWR EV/EBITDA Ratio Metrics

ARWR EV/Assets Ratio Metrics

ARWR EV/Sales Ratio Metrics

ARWR Current Ratio Metrics

ARWR Quick Ratio Metrics

ARWR ROIC Metrics

ARWR Return on Assets Metrics

ARWR Return on Equity Metrics

ARWR Net Profit Margin Metrics

ARWR Gross Profit Margin Metrics

ARWR Tax Rate Metrics

PS Ratio	13.35
PS Ratio Avg TTM	12.79
PS Ratio Avg 3Y	33.73
Current VS TTM Avg	+4.35%
Current VS 3Y Avg	-60.43%
Current VS 5Y Avg	-38.54%

PB Ratio	19.20
PB Ratio Avg TTM	17.13
PB Ratio Avg 3Y	13.61
Current VS TTM Avg	+12.08%
Current VS 3Y Avg	+41.09%
Current VS 5Y Avg	+61.98%

PFCF Ratio	34.06
PFCF Ratio Avg TTM	106.69
PFCF Ratio Avg 3Y	106.69
Current VS TTM Avg	-68.07%
Current VS 3Y Avg	-68.07%
Current VS 5Y Avg	-18.65%

Debt/Equity Ratio	1.86
Debt/Equity Ratio Avg TTM	1.36
Debt/Equity Ratio Avg 3Y	1.29
Current VS TTM Avg	+36.59%
Current VS 3Y Avg	+44.15%
Current VS 5Y Avg	+132.12%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	2.94%
FCF Yield Avg TTM	1.96%
FCF Yield Avg 3Y	1.96%
Current VS TTM Avg	+49.82%
Current VS 3Y Avg	+49.82%
Current VS 5Y Avg	+18.42%

Earnings Yield	1.98%
Earnings Yield Avg TTM	2.41%
Earnings Yield Avg 3Y	2.41%
Current VS TTM Avg	-17.74%
Current VS 3Y Avg	-17.74%
Current VS 5Y Avg	-17.74%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	36.86
Ev/Ebit Ratio Avg TTM	57.60
Ev/Ebit Ratio Avg 3Y	57.60
Current VS TTM Avg	-36.01%
Current VS 3Y Avg	-36.01%
Current VS 5Y Avg	-36.01%

Ev/Ebitda Ratio	34.02
Ev/Ebitda Ratio Avg TTM	48.39
Ev/Ebitda Ratio Avg 3Y	48.39
Current VS TTM Avg	-29.70%
Current VS 3Y Avg	-29.70%
Current VS 5Y Avg	-29.70%

Ev/Assets Ratio	4.62
Ev/Assets Ratio Avg TTM	5.64
Ev/Assets Ratio Avg 3Y	4.17
Current VS TTM Avg	-18.12%
Current VS 3Y Avg	+10.83%
Current VS 5Y Avg	+0.50%

Ev/Sales Ratio	14.56
Ev/Sales Ratio Avg TTM	13.66
Ev/Sales Ratio Avg 3Y	37.60
Current VS TTM Avg	+6.56%
Current VS 3Y Avg	-61.27%
Current VS 5Y Avg	-30.98%

Current Ratio	5.90
Current Ratio Avg TTM	5.05
Current Ratio Avg 3Y	5.43
Current VS TTM Avg	+16.85%
Current VS 3Y Avg	+8.64%
Current VS 5Y Avg	+26.18%

Quick Ratio	5.90
Quick Ratio Avg TTM	5.05
Quick Ratio Avg 3Y	5.42
Current VS TTM Avg	+16.85%
Current VS 3Y Avg	+8.86%
Current VS 5Y Avg	+25.75%

ROIC	(12.12%)
ROIC Avg 3Y	(28.42%)
ROIC Avg 5Y	(27.41%)
Current VS 3Y Avg	+57.37%
Current VS 5Y Avg	+55.78%
Current VS 10Y Avg	+56.36%

ROA	(15.15%)
ROA Avg TTM	(5.51%)
ROA Avg 3Y	(11.71%)
Current VS TTM Avg	-175.08%
Current VS 3Y Avg	-29.40%
Current VS 5Y Avg	-70.08%

ROE	(68.73%)
ROE Avg TTM	(22.18%)
ROE Avg 3Y	(63.87%)
Current VS TTM Avg	-209.82%
Current VS 3Y Avg	-7.61%
Current VS 5Y Avg	-61.72%

Net Profit Margin	(47.79%)
Net Profit Margin Avg TTM	(213.38%)
Net Profit Margin Avg 3Y	(211.86%)
Current VS TTM Avg	+77.60%
Current VS 3Y Avg	+77.44%
Current VS 5Y Avg	+66.99%

Gross Profit Margin	100.00%
Gross Pft Margin Avg TTM	100.00%
Gross Pft Margin Avg 3Y	64.25%
Current VS TTM Avg	0.00%
Current VS 3Y Avg	+55.64%
Current VS 5Y Avg	+4.83%

Tax Rate	0.10%
Tax Rate Avg 3Y	13.99%
Tax Rate Avg 5Y	11.19%
Current VS 3Y Avg	-99.27%
Current VS 5Y Avg	-99.08%
Current VS 10Y Avg	-98.39%